Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193684 · ClinicalTrials.gov registry record · Phase 4
Empagliflozin and Hepatic Glucose Metabolism
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT03193684 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 72 participants.
The verdict
NCT03193684, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake
Interventions
- DRUG Empagliflozin 25 MG
- DRUG Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-05-20 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193684
The ClinicalTrials.gov registry entry for NCT03193684 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Empagliflozin 25 MG is the first listed.
NCT03193684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03193684 about?
NCT03193684 is a clinical study titled "Empagliflozin and Hepatic Glucose Metabolism". the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake
What is the current status of trial NCT03193684?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2018-05-20. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03193684?
The interventions under investigation include: Empagliflozin 25 MG (DRUG), Control (DRUG).
Who is sponsoring clinical trial NCT03193684?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.